The National Survey on Drug Use and Health (NSDUH) series (formerly titled National Household Survey on Drug Abuse) primarily measures the prevalence and correlates of drug use in the United States. The surveys are designed to provide quarterly, as well as annual, estimates. Information is provided on the use of illicit drugs, alcohol, and tobacco among members of United States households aged 12 and older. Questions included age at first use as well as lifetime, annual, and past-month usage for the following drug classes: marijuana, cocaine (and crack), hallucinogens, heroin, inhalants, alcohol, tobacco, and nonmedical use of prescription drugs, including pain relievers, tranquilizers, stimulants, and sedatives. The survey covered substance abuse treatment history and perceived need for treatment, and included questions from the Diagnostic and Statistical Manual (DSM) of Mental Disorders that allow diagnostic criteria to be applied. The survey included questions concerning treatment for both substance abuse and mental health-related disorders. Respondents were also asked about personal and family income sources and amounts, health care access and coverage, illegal activities and arrest record, problems resulting from the use of drugs, and needle-sharing. Questions introduced in previous administrations were retained in the 2014 survey, including questions asked only of respondents aged 12 to 17. These "youth experiences" items covered a variety of topics, such as neighborhood environment, illegal activities, drug use by friends, social support, extracurricular activities, exposure to substance abuse prevention and education programs, and perceived adult attitudes toward drug use and activities such as school work. Several measures focused on prevention-related themes in this section. Also retained were questions on mental health and access to care, perceived risk of using drugs, perceived availability of drugs, driving and personal behavior, and cigar smoking. Questions on the tobacco brand used most often were introduced with the 1999 survey. For the 2008 survey, adult mental health questions were added to measure symptoms of psychological distress in the worst period of distress that a person experienced in the past 30 days and suicidal ideation. In 2008, a split-sample design also was included to administer separate sets of questions (WHODAS vs. SDS) to assess impairment due to mental health problems. Beginning with the 2009 NSDUH, however, all of the adults in the sample received only the WHODAS questions. Background information includes gender, race, age, ethnicity, marital status, educational level, job status, veteran status, and current household composition.

This data set includes the estimated number of individuals in Pennsylvania with Drug Use Disorder, which is an approximation for Opioid Use Disorder prevalence. The estimates are developed by applying mortality weights derived from the CDC’s National Center for Health Statistics to statewide illicit drug use estimates from the National Survey on Drug Use and Health (NSDUH, sponsored by the Substance Abuse and Mental Health Services Administration).

For those interested in data on student drug addiction in 2024, several sources offer valuable datasets and statistics.

1. Kaggle Dataset: Kaggle hosts a specific dataset on student drug addiction. This dataset includes various attributes related to student demographics, substance use patterns, and associated behavioral factors. It's a useful resource for data analysis and machine learning projects focused on understanding drug addiction among students【5†source】.

2. National Survey on Drug Use and Health (NSDUH): This comprehensive survey provides detailed annual data on substance use and mental health across the United States, including among students. It covers a wide range of substances and demographic details, helping to track trends and the need for treatment services【6†source】【8†source】.

3. Monitoring the Future (MTF) Survey: Conducted by the National Institute on Drug Abuse (NIDA), this survey tracks drug and alcohol use and attitudes among American adolescents. It provides annual updates and is an excellent source for understanding trends in substance use among high school and college students【7†source】.

4. Australian Institute of Health and Welfare (AIHW): For those interested in a more global perspective, the AIHW offers data from the National Drug Strategy Household Survey, which includes information on youth and young adult drug use in Australia. This can be useful for comparative studies【10†source】.

For detailed datasets and further analysis, you can explore these resources directly:

• Kaggle Student Drugs Addiction Dataset
• NSDUH Data
• Monitoring the Future
• AIHW Drug Survey

Data on drug overdose death rates, by drug type and selected population characteristics. Please refer to the PDF or Excel version of this table in the HUS 2019 Data Finder (https://www.cdc.gov/nchs/hus/contents2019.htm) for critical information about measures, definitions, and changes over time. SOURCE: NCHS, National Vital Statistics System, numerator data from annual public-use Mortality Files; denominator data from U.S. Census Bureau national population estimates; and Murphy SL, Xu JQ, Kochanek KD, Arias E, Tejada-Vera B. Deaths: Final data for 2018. National Vital Statistics Reports; vol 69 no 13. Hyattsville, MD: National Center for Health Statistics.2021. Available from: https://www.cdc.gov/nchs/products/nvsr.htm. For more information on the National Vital Statistics System, see the corresponding Appendix entry at https://www.cdc.gov/nchs/data/hus/hus19-appendix-508.pdf.

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year. DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit. The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 16 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.This study has 1 Data Set.

The National Survey on Drug Use and Health (NSDUH) provides national and state-level data on the use of tobacco, alcohol, illicit drugs (including non-medical use of prescription drugs) and mental health in the United States. This annual survey involves interviews with approximately 70,000 randomly selected individuals aged 12 and older. NSDUH is sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA), an agency of the U.S. Public Health Service in the U.S. Department of Health and Human Services (DHHS).

The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year. DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit. The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 16 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.This study has 1 Data Set.

Abstract (en): This series measures the prevalence and correlates of drug use in the United States. The surveys are designed to provide quarterly, as well as annual, estimates. Information is provided on the use of illicit drugs, alcohol, tobacco, and nonmedical use of prescription drugs among members of United States households aged 12 and older. Questions include age at first use, as well as lifetime, annual, and past-month usage for the following drug classes: cannabis, cocaine, hallucinogens, heroin, alcohol, tobacco, and nonmedical use of prescription drugs, including psychotherapeutics. Respondents were also asked about problems resulting from their use of drugs, alcohol, and tobacco, their perceptions of the risks involved, and personal and family income sources and amounts. Half of the respondents were asked questions regarding substance use by close friends. Demographic data include gender, race, age, ethnicity, educational level, job status, income level, veteran status, household composition, and population density. Youth respondents were also asked about time spent on homework and leisure activities. ICPSR data undergo a confidentiality review and are altered when necessary to limit the risk of disclosure. ICPSR also routinely creates ready-to-go data files along with setups in the major statistical software formats as well as standard codebooks to accompany the data. In addition to these procedures, ICPSR performed the following processing steps for this data collection: Performed consistency checks.; Created online analysis version with question text.; Checked for undocumented or out-of-range codes.. Response Rates: The interview completion rates for the three age groups were: 84 percent for youth, 81 percent for young adults, and 77 percent for older adults. The civilian, noninstitutionalized population of the coterminous United States (Alaska and Hawaii excluded) aged 12 and older. Multistage area probability sample design involving five selection stages: (a) primary areas (e.g., counties), (b) subareas within primary areas (geographic area of approximately 2,500 population in 1970), (c) housing units within subareas, (d) age group domains within listed units, and (e) members of households within sampled age groups. The two race classifications were: White, and Black/other. The three age groups were: youth (age 12 to 17), young adult (age 18 to 34), and older adult (age 35 and older). Each age group was sampled separately, and the probability of selection decreased with the prospective respondent's age. One youth and/or one adult could be chosen per household. The basic national sample was supplemented by a sample of residents of rural areas. The overall interview completion rate was 81 percent. 2015-11-23 Covers for the PDF documentation were revised.2015-02-03 Created a separate Questionnaire PDF that was extracted from the Codebook PDF.2013-06-19 Updated variable-level ddi files released.2008-06-18 New files were added. These files included one or more of the following: Stata setup, SAS transport (CPORT), SPSS system, Stata system, SAS supplemental syntax, and Stata supplemental syntax files, and tab-delimited ASCII data file. Also added variable CASEID to the dataset.1999-05-12 SAS and SPSS data definition statements have been updated to include value labels and missing values sections. Funding insitution(s): United States Department of Health and Human Services. National Institutes of Health. National Institute on Drug Abuse. personal interviews and self-enumerated answer sheets (drug use)Data were collected by Response Analysis Corporation, Princeton, NJ, under contract with the National Institute on Drug Abuse. The data and codebook were prepared for release by Research Triangle Institute, Research Triangle Park, NC, and the codebook was initially distributed by National Opinion Research Center, Chicago, IL, under contracts with the Substance Abuse and Mental Health Services Administration.For selected variables, statistical imputation was done following logical imputation to replace missing responses. These variables are identified by the designation "IMPUTATION-REVISED" in the variable label, and the names of these variables begin with the letters "IR". For each imputation-revised variable there is a corresponding imputation indicator variable that indicates whether a case's value on the variable resulted from an interview response, logical imputation, or statistical imputation. The names of ...

The National Registry for the Treatment of Drug Users (NRLUD) is a registry focused on the collection of data on patients entering and exiting addiction treatment, including contact, counseling and resocialization programs for drug users, i.e. data collection, verification, storage, protection and processing. This register provides summary data for statistical overviews at both national and international levels, as well as for epidemiological studies and health research. The data will be used in the creation of the drug policy and strategy of the Czech Republic and in the international context as well as in the EU.

The treatment request indicator is one of the five key indicators of drug epidemiology established by the European Monitoring Center for Drugs and Drug Addiction (hereafter EMCDDA), the collection of which is imposed on EU member states in Article 5 of Regulation (EC) No. 1920/2006 of the European Parliament and of the Council on December 12, 2006. The monitoring of treatment requests is part of the Drug Information System, the implementation of which is envisaged by a number of government resolutions on national drug policy strategies and their action plans, currently on the National Drug Policy Strategy for the period 2010–2018 and the action plan for the period 2010–2012. Treatment together with social reintegration and harm reduction, i.e. reducing the negative consequences of drug use, are two of the four pillars of the Czech anti-drug strategy. Without monitoring developments in the provision of treatment and specialized services to drug users, developments in these areas of drug policy cannot be monitored and evaluated.

Statistical unit of inquiry: A statistical unit is a person with problems caused by the use of addictive substances or a person addicted to them who entered or was included in a program aimed at counseling and addiction treatment carried out by treatment and counseling facilities.

This data set includes the estimated number of individuals in Pennsylvania with Drug Use Disorder, which is an approximation for Opioid Use Disorder prevalence. The estimates are developed by applying mortality weights derived from the CDC’s National Center for Health Statistics to statewide illicit drug use estimates from the National Survey on Drug Use and Health (NSDUH, sponsored by the Substance Abuse and Mental Health Services Administration).

The Residential Substance Abuse Treatment (RSAT) for State Prisoners Formula Grant Program, created by Title III (Subtitle U of the Violent Crime Control and Law Enforcement Act of 1994), was designed by Congress to implement residential substance abuse programs providing individual and group treatment for inmates in residential facilities operated by state and local correctional agencies. Under the Corrections Program Office of the Office of Justice Programs of the United States Department of Justice, state and local correctional agencies received funds to develop or enhance existing programs that: (1) lasted between six and 12 months, (2) provided residential treatment facilities set apart from the general correctional population, (3) were directed at the substance abuse problems of the inmate, (4) were intended to develop the inmate's cognitive, behavioral, social, vocational, and other skills in order to treat related problems as well as the substance abuse, and (5) continued to require urinalysis and/or other proven reliable forms of drug and alcohol testing of individuals assigned to treatment programs during and after release from residential custody. The National Development and Research Institutes, Inc. (NDRI) entered into a cooperative agreement with the National Institute of Justice wherein NDRI would evaluate the extent to which the goals of the RSAT program were being accomplished and the problems that were encountered by the participating states. The methods of this national evaluation were: (1) an initial state survey to ascertain the RSAT programs and program directors in each of the 50 states plus five territories and the District of Columbia and to collect basic information on the aggregate impact of the RSAT-funded programs in each state or territory (Part 1, State Data), (2) a follow-up state survey to collect more detailed information on the aggregate impact of the RSAT-funded programs in each state (Part 1, State Data), and (3) an initial program survey to describe the separate RSAT programs as they came on line and to assess whether a few of the programs might serve as model programs which could undergo subsequent intensive evaluation (Part 2, Program Data). The sampling method used was a census of all the existing RSAT-funded programs and all of the state RSAT officials. Part 1 variables include the amount of RSAT funds received by the state in fiscal years 1996 to 1998, amounts from other sources of funding, and amount spent on salaries, training, drug tests, other supplies, and facilities, as well as number of residents, number of staff, reasons why funding was delayed, RSAT award date, and RSAT end date. Part 2 variables include the number of clients in the program, number of beds available, number of staff by gender, race, age, education, profession, and years of experience, admission inclusion criteria, reporting procedures, treatment type and duration, type of drug testing and number of tests, annual budget, sources of funding, and cost per capita.

Analysis of ‘💉 Opioid Overdose Deaths’ provided by Analyst-2 (analyst-2.ai), based on source dataset retrieved from https://www.kaggle.com/yamqwe/opioid-overdose-deathse on 13 February 2022.

--- Dataset description provided by original source is as follows ---

About this dataset

Opioid addiction and death rates in the U.S. and abroad have reached "epidemic" levels. The CDC's data reflects the incredible spike in overdoses caused by drugs containing opioids.

The United States is experiencing an epidemic of drug overdose (poisoning) deaths. Since 2000, the rate of deaths from drug overdoses has increased 137%, including a 200% increase in the rate of overdose deaths involving opioids (opioid pain relievers and heroin). Source: CDC

In-the-News:

• STAT: 26 overdoses in just hours: Inside a community on the front lines of the opioid epidemic
• NPR: Organ Donations Spike In The Wake Of The Opioid Epidemic, Deadly Opioid Overwhelms First Responders And Crime Labs in Ohio
• Scientific American: Wave of Overdoses with Little-Known Drug Raises Alarm Amid Opioid Crisis
• Washington Post: A 7-year-old told her bus driver she couldn’t wake her parents. Police found them dead at home.
• Wall Street Journal: For Small-Town Cops, Opioid Scourge Hits Close to Home
• Food & Drug Administration: FDA launches competition to spur innovative technologies to help reduce opioid overdose deaths

This data was compiled using the CDC's WONDER database. Opioid overdose deaths are defined as: deaths in which the underlying cause was drug overdose, and the ICD-10 code used was any of the following: T40.0 (Opium), T40.1 (Heroin), T40.2 (Other opioids), T40.3 (Methadone), T40.4 (Other synthetic narcotics), T40.6 (Other and unspecified narcotics).

Age-adjusted rate of drug overdose deaths and drug overdose deaths involving opioids
http://i.imgur.com/ObpzUKq.gif" alt="Opioid Death Rate" style="">
Source: CDC

What are opioids?
Opioids are substances that act on opioid receptors to produce morphine-like effects. Opioids are most often used medically to relieve pain. Opioids include opiates, an older term that refers to such drugs derived from opium, including morphine itself. Other opioids are semi-synthetic and synthetic drugs such as hydrocodone, oxycodone and fentanyl; antagonist drugs such as naloxone and endogenous peptides such as the endorphins.[4] The terms opiate and narcotic are sometimes encountered as synonyms for opioid. Source: Wikipedia

contributors-wanted See comment in Discussion

Footnotes

• The crude rate is per 100,000.
• Certain totals are hidden due to suppression constraints. More Information: http://wonder.cdc.gov/wonder/help/faq.html#Privacy.
• The population figures are briged-race estimates. The exceptions being years 2000 and 2010, in which Census counts are used.
• v1.1: Added Opioid Prescriptions Dispensed by US Retailers in that year (millions).

Citation: Centers for Disease Control and Prevention, National Center for Health Statistics. Multiple Cause of Death 1999-2014 on CDC WONDER Online Database, released 2015. Data are from the Multiple Cause of Death Files, 1999-2014, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. Accessed at http://wonder.cdc.gov/mcd-icd10.html on Oct 19, 2016 2:06:38 PM.

Citation for Opioid Prescription Data: IMS Health, Vector One: National, years 1991-1996, Data Extracted 2011. IMS Health, National Prescription Audit, years 1997-2013, Data Extracted 2014. Accessed at NIDA article linked (Figure 1) on Oct 23, 2016.

Data Use Restrictions:
The Public Health Service Act (42 U.S.C. 242m(d)) provides that the data collected by the National Center for Health Statistics (NCHS) may be used only for the purpose for which they were obtained; any effort to determine the identity of any reported cases, or to use the information for any purpose other than for health statistical reporting and analysis, is against the law. Therefore users will:
Use these data for health statistical reporting and analysis only.
For sub-national geography, do not present or publish death counts of 9 or fewer or death rates based on counts of nine or fewer (in figures, graphs, maps, tables, etc.).
Make no attempt to learn the identity of any person or establishment included in these data.
Make no disclosure or other use of the identity of any person or establishment discovered inadvertently and advise the NCHS Confidentiality Officer of any such discovery.
Eve Powell-Griner, Confidentiality Officer
National Center for Health Statistics
3311 Toledo Road, Rm 7116
Hyattsville, MD 20782
Telephone 301-458-4257 Fax 301-458-4021

This dataset was created by Health and contains around 800 samples along with Crude Rate, Crude Rate Lower 95% Confidence Interval, technical information and other features such as: - Year - Deaths - and more.

How to use this dataset

• Analyze Crude Rate Upper 95% Confidence Interval in relation to Prescriptions Dispensed By Us Retailers In That Year (millions)
• Study the influence of State on Crude Rate
• More datasets

Acknowledgements

If you use this dataset in your research, please credit Health

Start A New Notebook!

--- Original source retains full ownership of the source dataset ---

The National Hospital Care Survey (NHCS) collects data on patient care in hospital-based settings to describe patterns of health care delivery and utilization in the United States. Settings currently include inpatient and emergency departments (ED). From this collection, the NHCS contributes data that may inform emerging national health threats such as the current opioid public health emergency. The 2022 - 2024 NHCS are not yet fully operational so it is important to note that the data presented here are preliminary and not nationally representative. The data are from 24 hospitals submitting inpatient and 23 hospitals submitting ED Uniform Bill (UB)-04 administrative claims from October 1, 2022–September 30, 2024. Even though the data are not nationally representative, they can provide insight into the use of opioids and other overdose drugs. The NHCS data is submitted from various types of hospitals (e.g., general/acute, children’s, etc.) and can show results from a variety of indicators related to drug use, such as overall drug use, comorbidities, and drug and polydrug overdose. NHCS data can also be used to report on patient conditions within the hospital over time.

The National Hospital Care Survey (NHCS) collects data on patient care in hospital-based settings to describe patterns of health care delivery and utilization in the United States. Settings currently include inpatient and emergency departments (ED). From this collection, the NHCS contributes data that may inform emerging national health threats such as the current opioid public health emergency. The 2023 - 2024 NHCS are not yet fully operational so it is important to note that the data presented here are preliminary and not nationally representative.

The data are from 47 hospitals submitting inpatient and 39 hospitals submitting ED Uniform Bill (UB)-04 administrative claims from January 1, 2023–December 31, 2024. Even though the data are not nationally representative, they can provide insight into the use of opioids and other overdose drugs. The NHCS data is submitted from various types of hospitals (e.g., general/acute, children’s, etc.) and can show results from a variety of indicators related to drug use, such as overall drug use, comorbidities, and drug and polydrug overdose. NHCS data can also be used to report on patient conditions within the hospital over time.

The National Survey of Substance Abuse Treatment Services (N-SSATS) is designed to collect information from all facilities in the United States, both public and private, that provide substance abuse treatment. N-SSATS provides the mechanism for quantifying the dynamic character and composition of the United States substance abuse treatment delivery system. The objectives of N-SSATS are to collect multipurpose data that can be used to assist the Substance Abuse and Mental Health Services Administration (SAMHSA) and state and local governments in assessing the nature and extent of services provided and in forecasting treatment resource requirements, to update SAMHSA's Inventory of Substance Abuse Treatment Services (I-SATS), to analyze general treatment services trends, and to generate the National Directory of Drug and Alcohol Abuse Treatment Programs and its online equivalent, the Substance Abuse Treatment Facility Locator http://findtreatment.samhsa.gov. Data are collected on topics including facility operation, services offered (assessment and pre-treatment, pharmacotherapies, testing, transitional, ancillary), detoxification, primary focus (substance abuse, mental health, both, general health, and other), hotline operation, Opioid Treatment Programs and medication dispensed/prescribed, counseling and therapeutic approaches, languages in which treatment is provided, type of treatment provided, number of clients (total and under age 18), number of beds, types of payment accepted, sliding fee scale, special programs offered, facility accreditation and licensure/certification, and managed care agreements.This study has 1 Data Set.

Data on use of selected substances in the past 30 days among 12th graders, 10th graders, and 8th graders in the United States, by sex and race. Data are from Health, United States. Source: Monitoring the Future, Institute for Social Research, University of Michigan, supported by National Institutes of Health, National Institute on Drug Abuse. Search, visualize, and download these and other estimates from over 120 health topics with the NCHS Data Query System (DQS), available from: https://www.cdc.gov/nchs/dataquery/index.htm.

Data on use of selected substances in the past 30 days among 12th graders, 10th graders, and 8th graders in the United States, by sex and race. Data are from Health, United States. Source: Monitoring the Future, Institute for Social Research, University of Michigan, supported by National Institutes of Health, National Institute on Drug Abuse. Search, visualize, and download these and other estimates from over 120 health topics with the NCHS Data Query System (DQS), available from: https://www.cdc.gov/nchs/dataquery/index.htm.

The primary objective of the National Pregnancy and Health Survey (NPHS) was to produce national annual estimates of the percentages and numbers of mothers of live newborns in the United States who used selected licit and illicit drugs in the 12 months prior to delivery. A further objective was to describe patterns of prenatal substance use among demographic subgroups of women. Information on demographic and socioeconomic characteristics, obstetric history, and drug treatment of women who delivered infants at sampled hospitals was obtained through an interviewer-administered questionnaire, while data on substance use before and during pregnancy were collected through a questionnaire completed by the respondent and concealed from the interviewer. Respondents were asked about use of the following substances: alcohol, amphetamines, analgesics, cocaine, crack cocaine, barbiturates, hallucinogens, hashish, heroin, marijuana, methadone, methamphetamine, sedatives, stimulants, tobacco, and tranquilizers. Additionally, information was collected on the respondent's pregnancy, prenatal care, delivery, previous pregnancies, and background. Additional data were obtained from the mothers' and infants' medical records. Urine specimens collected routinely by the hospital on obstetric admissions were tested for selected drugs. Finally, in a subsample of six hospitals, hair specimens were requested from respondents to evaluate the potential of hair as a source of toxicological data in future studies.

The National Survey of Substance Abuse Treatment Services (N-SSATS) is designed to collect information from all facilities in the United States, both public and private, that provide substance abuse treatment. N-SSATS provides the mechanism for quantifying the dynamic character and composition of the United States substance abuse treatment delivery system. The objectives of N-SSATS are to collect multipurpose data that can be used to assist the Substance Abuse and Mental Health Services Administration (SAMHSA) and state and local governments in assessing the nature and extent of services provided and in forecasting treatment resource requirements, to update SAMHSA's Inventory of Behavioral Health Services (I-BHS), to analyze general treatment services trends, and to generate the online Substance Abuse Treatment Facility Locator http://findtreatment.samhsa.gov, as well as the National Directory of Drug and Alcohol Abuse Treatment Programs.Data are collected on topics including facility operation, services offered (assessment, testing, transitional, ancillary, and pharmacotherapies), detoxification, primary focus (substance abuse, mental health, both, general health, and other), Opioid Treatment Programs and medications dispensed/prescribed, counseling and therapeutic approaches, standard operating procedures, special programs/groups offered, languages in which treatment is provided, type of treatment provided (hospital inpatient, residential, outpatient), number of clients (by service, total, and under age 18), number of beds, types of payment accepted, sliding fee scale, and facility accreditation and licensure/certification.This study has 1 Data Set.

The Strategic Prevention Framework State Incentive Grant (SPF SIG) National Cross-Site Evaluation was conducted to evaluate the Center for Substance Abuse Prevention (CSAP)'s SPF SIG initiative, which sought to: (1) prevent the onset and reduce the progression of substance abuse, including childhood and underage drinking; (2) reduce substance abuse-related problems in communities; and (3) build prevention capacity and infrastructure at the state and community levels. This cross-site evaluation included the 21 states and territories CSAP funded in FY2004 (Cohort 1) and an additional 5 States funded in Cohort 2 in FY2005 that were funded for up to 5 years to implement the SPF. The SPF is a five-step prevention planning model that requires states to: (1) conduct a statewide needs assessment, including the establishment of a State Epidemiological and Outcomes Workgroup (SEOW); (2) mobilize and build state and community capacity to address needs; (3) develop a statewide strategic plan for prevention; (4) implement evidence-based prevention, policies, and practices (EBPPP) to meet state and community needs; and (5) monitor and evaluate the implementation of their SPF SIG project. Under contract to the Substance Abuse and Mental Health Services Administration (SAMHSA) with funding provided by the National Institute on Drug Abuse (NIDA), Westat, in collaboration with the Pacific Institute for Research and Evaluation (PIRE) and The MayaTech Corporation, implemented a multilevel, multi-method quasi-experimental design to evaluate SPF SIG's impact. The scope of the evaluation encompassed national, state, and community levels. The design included comparison conditions at both the state and community levels. These data represent Phase I of the restricted use data release and contains extensive data on state-level implementation, community-level implementation, and state-level infrastructure, as well as other reference elements. A subsequent release (Phase II) will include state- and community-level outcomes, as well as data on community-level implementation, community-level implementation fidelity, state-level sustainability, and mediating variables.